SCHEMBL17453066

SCHEMBL17453066

CCN1C(=N)N[C@](C)(c2cc([N+](=O)[O-])ccc2F)CS1(=O)=NC

nearest known ligand 0.39

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
BACE2 Q9Y5Z0 3/20 0.39
BACE1 P56817 3/20 0.39
ALDH1A1 P00352 4/20 0.33
GAA P10253 2/20 0.33
THRB P10828 1/20 0.33
HTT P42858 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
HIF1A Q16665 1/20 0.33
AKR1B1 P15121 1/20 0.31
ADRA2A P08913 1/20 0.31
PNMT P11086 1/20 0.31
ADRA2B P18089 1/20 0.31
ADRA2C P18825 1/20 0.31
CYP1A2 P05177 1/20 0.31
POLB P06746 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17453057 0.87 BACE1 (0.41) BACE2BACE1ALDH1A1HIF1AAKR1B1
SCHEMBL17453063 0.83 BACE2 (0.39) BACE2BACE1ALDH1A1GAATHRB
SCHEMBL17652908 0.79 BACE2 (0.43) BACE2BACE1ALDH1A1HIF1AAKR1B1
SCHEMBL29554687 0.79 BACE2 (0.43) BACE2BACE1ALDH1A1HIF1AAKR1B1
SCHEMBL10328607 0.79 BACE2 (0.43) BACE2BACE1ALDH1A1HIF1AAKR1B1
SCHEMBL13466034 0.75 BACE1 (0.47) BACE2BACE1ALDH1A1HIF1AAKR1B1
SCHEMBL13466659 0.75 BACE1 (0.44) BACE2BACE1ALDH1A1GAATHRB
SCHEMBL13466444 0.75 BACE1 (0.44) BACE2BACE1ALDH1A1GAATHRB
SCHEMBL17454892 0.74 BACE1 (0.69) BACE2BACE1
SCHEMBL13466661 0.73 BACE1 (0.42) BACE2BACE1ALDH1A1GAATHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9428476-B2 S-imino-S-oxo-iminothiadiazine compounds as BACE inhibitors, compositions, and their use MERCK SHARP & DOHME CORP. (US) 2016-08-30 US disclosed
US-9428476-B2 S-imino-S-oxo-iminothiadiazine compounds as BACE inhibitors, compositions, and their use MERCK SHARP & DOHME CORP. (US) 2016-08-30 US disclosed
US-20160016923-A1 S-IMINO-S-OXO-IMINOTHIADIAZINE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE MERCK SHARP & DOHME CORP. (US) 2016-01-21 US disclosed
US-20160016923-A1 S-IMINO-S-OXO-IMINOTHIADIAZINE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE MERCK SHARP & DOHME CORP. (US) 2016-01-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160016923-A1 S-IMINO-S-OXO-IMINOTHIADIAZINE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE BACE1, BACE2, APP BACE2 2/4885BACE1 1/4885ALDH1A1 335/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.